Craft
  • Home
  •  / Roivant Sciences
Roivant Sciences

Roivant Sciences

Registration Phase Products

1

Q2, 2021

Revenue

$55.3 M

FY, 2022

Market Capitalization

$3.4 B

2022-11-18

Roivant Sciences Summary

Company summary

Overview
Roivant Sciences is a company that develops and commercializes medicines. It provides drug candidates focusing on a range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, as well as rare and fatal pediatric conditions. The company also offers the Roivant platform and technologies built to address inefficiencies in the drug discovery, development, and commercialization process.
Type
Public
Status
Active
Founded
2014
HQ
London, GB | view all locations
Website
http://roivant.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Matt Gline

    Matt Gline, Chief Executive Officer

  • Vivek Ramaswamy

    Vivek Ramaswamy, Founder, Executive Chairman

  • Eric Venker

    Eric Venker, President & Chief Operating Officer

  • Mayukh Sukhatme

    Mayukh Sukhatme, President & Chief Investment Officer

Operating MetricsView all

Drug Candidates

30

FY, 2020

Registration Phase Products

1

Q2, 2021

Phase I Trials Products

4

Q2, 2021

LocationsView all

4 locations detected

  • London, England HQ

    United Kingdom

    3rd Floor, 11-12 St James's Square, St. James's

  • Boston, MA

    United States

    451 D St

  • New York, NY

    United States

    151 W 42nd St 15th Floor

  • Basel, BS

    Switzerland

    Viaduktstrasse 8

Roivant Sciences Financials

Summary financials

Revenue (Q2, 2023)
$12.5M
Gross profit (Q2, 2023)
$11.1M
Net income (Q2, 2023)
($315.9M)
Cash (Q1, 2023)
$1.9B
EBIT (Q2, 2023)
($228.7M)
Enterprise value
$1.9B

Footer menu